Literature DB >> 24981388

From genes to drugs: target validation in Caenorhabditis elegans.

Ann E Sluder1, Ralf Baumeister2.   

Abstract

A central challenge in post-genomic drug discovery is selection of relevant therapeutic targets from a large pool of candidates, so that resources are invested productively. Key to meeting this challenge is demonstrating target function in disease-related pathways in vivo. The nematode Caenorhabditis elegans, a well-characterized experimental system for genetic analysis of biological regulatory pathways, provides a powerful means of assessing the impact of modulating target function on biological processes, thus facilitating selection of high-value targets.:
© 2004 Elsevier Ltd . All rights reserved.

Entities:  

Year:  2004        PMID: 24981388     DOI: 10.1016/j.ddtec.2004.09.007

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  4 in total

Review 1.  Caenorhabditis elegans in Chinese medicinal studies: making the case for aging and neurodegeneration.

Authors:  Qiangqiang Wang; Fan Yang; Wei Guo; Ju Zhang; Lingyun Xiao; Haifeng Li; Weizhang Jia; Zebo Huang
Journal:  Rejuvenation Res       Date:  2014-04-08       Impact factor: 4.663

2.  Gengnianchun, a Traditional Chinese Medicine, Enhances Oxidative Stress Resistance and Lifespan in Caenorhabditis elegans by Modulating daf-16/FOXO.

Authors:  Fanhui Meng; Jun Li; Wenjun Wang; Yan Fu
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-16       Impact factor: 2.629

3.  Liangyi Gao extends lifespan and exerts an antiaging effect in Caenorhabditis elegans by modulating DAF-16/FOXO.

Authors:  Liling Zeng; Chen Sun; Zhong Pei; Tianchan Yun; Shaoyi Fan; Simei Long; Tengteng Wu; Ziwen Chen; Zhimin Yang; Fuping Xu
Journal:  Biogerontology       Date:  2019-07-22       Impact factor: 4.277

4.  Antiaging effect of a Jianpi-yangwei formula in Caenorhabditis elegans.

Authors:  Liling Zeng; Zhimin Yang; Tianchan Yun; Shaoyi Fan; Zhong Pei; Ziwen Chen; Chen Sun; Fuping Xu
Journal:  BMC Complement Altern Med       Date:  2019-11-15       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.